December 21, 2016
A sincere note to wish all of you a special and very happy holiday season.
Our expectations as we move into the New Year are for the expanded ‘discovery’ of AsepticSure® and the wonders it offers for safer hospitals, not to mention the many other applications for the science. With regulatory approvals for US market entry now in hand and a solid FDA and EPA registered manufacturing partner in place with Cogmedix, we feel prepared. They are a company that we place great faith in as partners for this journey as we move into the future holding the anticipation of demand based manufacturing growth and product delivery requirements.
On December 15th, we held a meeting of shareholders in Salt Lake City. We thank our lead outside counsel, Durham, Jones and Pinegar, for graciously offering excellent accommodations and their support for the meeting. Management considers the meeting a success and thanks to all of our shareholders for your votes on the various proxy measures. An SEC Form 8K filing of the final voting results can be viewed by following the enclosed link.
While these meetings are always lightly attended, we wish to thank all of our shareholders that voted their proxy as well as those that attended. Currently, Medizone International has 2,305 shareholders of record with our stock transfer agent, American Stock Transfer and Trust and an additional 5,083 shareholders holding street stock in brokerage accounts.
Given the current level of interest we are seeing in AsepticSure, both in the United States and from other regions, we truly believe that we are now entering a year of expanded product recognition and acceptance. This is expected to lead to profitability, sustainable revenues and encouraging growth curves as we progress through the latter half of 2017.
We should always remember that while there are other products competing in the same market space, not one of them is capable of demonstrating what AsepticSure achieves. This truly is a revolutionary science that is destined to become the Gold Standard for the disinfection of enclosed spaces.
Being cautious and also realistic, please do not expect things to happen over night. Programs, production and opportunities are coming together. We are very optimistic and feel prepared for the coming growth we envision. I hope shareholders understand that this is the beginning of a new and exciting stage for our company so they can enjoy the journey. We only see upside from here.
May each of you enjoy a wonderful holiday. As an FYI, both our Canadian and US facilities will be closed from Christmas Eve, which is also the beginning of Hanukkah this year. We will reopen following New Year’s.
Blessings to all,
Edwin G. Marshall
Chairman of the Board
Chief Executive Officer
This Web Site Posting may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
For more information, visit: